GT BIOPHARMA INC (GTBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.24-4.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GTBP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.3 | 0.0 |
| Total Revenues | — | — | — | — | — | — | 0.0 | — | — | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.3 | 0.0 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 |
| Gross Profit | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | (0.0) |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 12.9 | 9.0 | 8.6 | 7.1 | 12.4 | 47.9 | 6.3 | 9.8 | 12.5 | 134.5 | 8.4 | 8.0 | 2.4 | 0.9 | 3.4 | 3.5 |
| R&D Expenses | 3.5 | 3.5 | 5.8 | 6.5 | 8.8 | 9.6 | 0.5 | 1.7 | 9.1 | 1.1 | 1.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Income | (16.3) | (12.4) | (14.4) | (13.6) | (21.3) | (57.5) | (6.8) | 16.1 | (250.1) | (135.6) | (9.4) | (8.9) | (2.4) | (0.8) | (3.5) | (3.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.1 | — | 0.2 | 0.0 | 0.7 | (3.0) | (2.1) | 9.1 | 8.6 | 6.6 | 17.0 | 5.1 | 1.2 | 1.7 | 0.6 |
| Other Non-Operating Income / Expenses | 0.2 | (15.9) | 1.2 | 6.0 | 0.4 | (0.5) | (21.5) | 22.6 | (9.1) | (8.6) | 19.1 | (12.5) | (21.1) | 0.2 | (1.7) | 0.2 |
| Asset Writedown | — | — | — | — | — | — | 0.0 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | (38.6) | (259.2) | (144.2) | 9.8 | (21.5) | (23.5) | (0.6) | (5.3) | (3.7) |
| Income Tax Expense | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | (0.0) | (0.1) | (0.1) | — |
| Net Income | (16.2) | (28.4) | (13.2) | (7.6) | (20.9) | (58.0) | (28.3) | (38.6) | (259.2) | (144.2) | 9.8 | (21.5) | (23.5) | (0.5) | (5.2) | (3.7) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.42) | (6.68) | (6.94) | (5.64) | (19.66) | (2.06) | — | — | (5.16) | (8.60) | 119.91 | — | — | — | — | — |
| Diluted EPS | (0.42) | (6.68) | (6.94) | (5.64) | (19.66) | — | — | — | (5.16) | (8.60) | 119.91 | — | — | — | — | — |
| Basic Weighted Avg Shares | 38.8 | 5.5 | 1.9 | 1.3 | 1.1 | 28.2 | — | — | 0.1 | 0.0 | 0.1 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 38.8 | 5.5 | 1.9 | 1.3 | 1.1 | — | 4.4 | 3.4 | 0.1 | 0.0 | 0.1 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBIT | (16.3) | (12.4) | (14.4) | (13.6) | (21.3) | (57.5) | (6.8) | 16.1 | (250.1) | (135.6) | (9.4) | (8.9) | (2.4) | (0.8) | (3.5) | (3.9) |
| Effective Tax Rate | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.